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the general public, as it is possible there are differences in the valuation of states
close to death.
PCN149
HEALTH STATE UTILITY VALUES IN BREAST CANCER: A REVIEW AND META-
ANALYSIS
Peasgood T1, Ward SE2, Brazier J1
1University of Sheffield, Sheffield, UK, 2Univerrsity of Sheffield, Sheffield, UK
OBJECTIVES:Health-related quality of life is an important issue in the treatment of
breast cancer (BC) and health-state utility values (HSUVs) are essential for cost-
utility analysis. The aim of the study was to identify published values for common
health states for breast cancer and to determine pooled estimates of HSUVs for
each identifiable health state. METHODS: A systematic review of HSUVs for condi-
tions relating to BC was undertaken. Thirteen databases were searched in March
2009. HSUVs were allocated to six categories: screening related states, preventative
states, adverse events in breast cancer and its treatment, non-specific breast can-
cer, early breast cancer (EBC) states and metastatic breast cancer (MBC) states.
Where appropriate meta analysis was used to provide utilities based on combining
all available evidence. Mean utility estimates were pooled using ordinary least
squares with utilities clustered within study group and weighted by both number
of respondents and inverse of the variance of each utility. Regressions included
controls for disease state, utility assessment method and other features of study
design. RESULTS: Forty-nine articles were identified, providing 476 unique utility
values. From these, 117 values for MBC and 230 values for EBC were extracted and
analysed by regression analysis. Utilities were found to vary significantly by valu-
ation method (e.g. in EBC standard gamble had higher valuations than TTO and
EQ-5D), and source of values. For MBC values significantly varied in expected di-
rection by severity of condition, treatment and side-effects. CONCLUSIONS: De-
spite the numerous studies it was not feasible to generate a definitive list of HSUVs
that could be used in future economic evaluations, due to the complexity of the
health states involved and the variety of methods used to obtain values. Future
research into quality of life in BC should make greater use of validated generic
preference-based measures for which public preferences exist.
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OBJECTIVES: The objective of this analysis was to assess patients’ willingness to
pay (WTP) for a reduction in risk of breast cancer treatment side effects.METHODS:
A survey was developed using continent valuation processes to assess the WTP for
a reduction in side effects. The survey asked female MBC patients to provide the
amount they were willing to pay for a 25%, 50% and 100% reduction in risk of the
following side effects: diarrhea/dehydration, hair loss, fatigue, nausea, neutrope-
nia/febrile neutropenia, pain and tingling in hands and feet. Patients were also
asked to select the side effect they would pay the most to avoid. Demographic
information such as age, race/ethnicity, region, employment status, insurance
type, and treatment regimen was also collected. RESULTS:A total of 202 metastatic
breast cancer patients completed the survey. The majority of respondents were
white, married, over the age of 51, and well educated. Most respondents had pri-
vate insurance (67%) or Medicare (24%). Of those who reported paying out of pocket
for their last treatment (58%), the average payment was $459. For a 25%, 50%, and
100% reduction in the risk of side effects, respondents were willing to pay an extra
$1886, $3837 and $7794, respectively. Hair loss (28%), pain (17%) and nausea (15%)
were selected most often as the side effect respondents would pay the most to
avoid. CONCLUSIONS: Patients with MBC highly value reduction in treatment side
effects and are WTP 4.2 times more for a treatment devoid of side effects over a
treatment with a 25% reduction in the risk of side effects. Additional research is
warranted to quantify WTP for specific side effects.
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OBJECTIVES: As outcomes research is being used to inform the decision-maker
about continuation of reimbursement of expensive hospital drugs in the The Neth-
erlands since 2006, this type of research is becoming more important. Our study
started before 2006 and aimed to evaluate therapies in daily clinical practice and
their costs and outcomes. This study gives an indication of the challenges that may
arise from the design of outcomes research.METHODS:An observational follow-up
study was performed including 160 patients with chronic lymphocytic leukemia
(CLL). Data collection on treatment, costs and outcome was performed in 19 Dutch
hospitals using medical records. RESULTS: Patients diagnosed between 1999 and
2003 were included and followed during 6.4 years on average. The mean age was 63
years (range: 30-86). 20% received one therapy-line, 12% two and 24% received three
or more therapy-lines. Most patients received chlorambucil (87%) as first therapy
and the second line was dominated by fludarabine (46%). However, therapies from
the third line onwards varied extensively. Due to the development of new medi-
cines like monoclonal antibodies, the treatment sequence changed in the more
recently diagnosed patients. As a consequence of the relatively low incidence of
CLL and the variety in therapy, the number of patients with comparable therapies
was small. CONCLUSIONS:Management of CLL varied strongly especially after the
second therapy-line. This may be caused by the introduction of monoclonal anti-
bodies as first and second line treatment during the study period. Additionally, a
comparison of alternative therapies was hampered due to relative small number of
patients. Consequently, modeling studies or patient registrations might be neces-
sary to obtain valid information about cost-effectiveness of new expensive inpa-
tient medicines in (chronic) diseases with a low incidence rate and a highly variable
or changing management strategy.
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OBJECTIVES: Controversy continues about screening mammography, partially be-
cause of risks involved. Pre-test breast cancer risk prediction may improve positive
and negative predictive value of screening mammography, particularly among
women who have an abnormal screening mammogram. METHODS: We modeled
one-year breast cancer risk in women with abnormal screening mammograms
(BI-RADS3, BI-RADS4) by combining estimates of pre-test breast cancer risk based
upon established risk factors, 12 validated SNPs and the average probability of
cancer given BI-RADS category. We examined the degree to which the incorpora-
tion of pre-test breast cancer risk would reclassify women from current recom-
mendations for short-term follow up of BI-RADS3 and biopsy of BI-RADS4 using
biopsy thresholds of 1, 2 and 3% probability of breast cancer. RESULTS: Women
with BI-RADS3 in the lowest 5% of pre-test breast cancer risk had a one-year aver-
age breast cancer risk of 0.24% compared to 2.7% for women in the highest 5% of
pre-test risk. Women with BI-RADS4 in the lowest 5% of pre-test risk had a one-year
average breast cancer risk of 4.9% compared to 39.8% for women in the highest 5%
of pre-test risk. Incorporating BI-RADS 4 subclassifications increased the risk dis-
crimination, women with BI-RADS 4A in the lowest 5% of pre-test probability had a
one-year breast cancer risk of 1.4%. Using a biopsy risk threshold of 2%, 8% of
women with a BI-RADS3 had a post-test risk above the threshold for biopsy and 7%
of women with BI-RADS4A had a post-test risk below the threshold.
CONCLUSIONS: Although incorporation of pre-test risk estimates changes deci-
sions about management of abnormal mammograms for a relatively small propor-
tion of women, the public health impact could be significant given the incidence of
abnormal mammograms. Prospective studies are needed to determine effective-
ness of breast cancer risk prediction in improving the positive and negative pre-
dictive value of mammography screening.
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OBJECTIVES: Although cancer morbidity is lower than cardiovascular or metabolic
diseases, it is still the second leading cause of mortality and also the major eco-
nomic problem due to high cost of treatment. According to estimations by the
Karolinska Institutet and Stockholm School of Economics, the direct costs of caring
for cancer patients are approximately 6.5% of total healthcare costs. The aim of this
study was to estimate cost of hospital care in population of patients with neo-
plasms in 2009. METHODS: We used National Health Fund (NHF) statistics on Di-
agnosis-Related Groups (DRGs) attrition in 2009 year. Precise, in respect to ICD-10
diagnosis, NHF statistics cover 85% of all data. We identified data only for malig-
nant neoplasms (C00-C97), in situ neoplasms (D00-D09) and neoplasms of uncer-
tain or unknown behavior (D37-D48). Values are presented in Euro (exchange rate:
1 EUR4.00 PLN). RESULTS: Cost of hospital care in population of patients with
neoplasms was estimated to amount of 246.3 million EUR (289.7 million EUR when
correction for 85% statistics cover will be applied). The highest costs of hospital
care were related to malignant neoplasm of bronchus and lung (34.3 million EUR)
followed by malignant neoplasm of bladder (26.5 million EUR), and malignant neo-
plasm of colon (22.8 million EUR). Given the number of cancer patients in Poland
which is estimated to be 270 thousands, cost of hospital care per cancer patient per
year would be approximately 1073 EUR. However apart from DRGs, cost of hospital
care in population of patients with neoplasms includes also separately contracted
chemotherapy (374.3 million EUR) and some Therapeutics Programs with a new
drugs such as trastuzumab in breast cancer (46.1 million EUR) . CONCLUSIONS:
Cost of hospital care in population of cancer patients is substantial and account for
over 11.5% of all costs of hospital care in Poland in 2009.
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OBJECTIVES: In the absence of national screening programs (NSP) for adults in
Greece, the aim of this study was to examine experts’ views and recommendations
on a predefined set of NSPs METHODS: A systematic review was conducted to
identify those screening programs that best meet the criteria of clinical effective-
ness and cost efficiency. The programs identified were set for evaluation in a multi-
professional expert panel which completed a structured questionnaire in three
rounds, using the Delphi method. Experts’ agreement was investigated as well as
A462 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) A 2 3 3 - A 5 1 0
